Amanda Feilding

Executive Director and Founder

Data updated

Papers

50 publications

Trials

0 clinical trials

Links

Research Footprint

Amanda Feilding appears in 50 tracked papers (2010–2025), most studied alongside LSD, Psilocybin and Ayahuasca, across Healthy Volunteers, Neuroimaging & Brain Measures and Depressive Disorders.

Most-cited paper: Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study (1520 citations).

Frequent co-authors: Robin Carhart-Harris, David Nutt and Mendel Kaelen.

Background & Research

Amanda Feilding (1943–2025) was a British drug policy reformer and the founder of the Beckley Foundation. Often described as the 'hidden hand' behind the psychedelic renaissance, she dedicated her life to the study of consciousness and the scientific validation of psychedelics. Through the Beckley Foundation, she collaborated on many of the first modern human studies with LSD, psilocybin, and MDMA.

Affiliations

Institutions, companies, and organisations Amanda Feilding is associated with.